Document:

EX-10.9

 Exhibit 10.9 

May 16, 2019 
 PERSONAL AND CONFIDENTIAL

 Mr. Chris Bradley 
 Chief Financial Officer

 Haymaker Acquisition Corp. II 
 650 Fifth Avenue, Floor 10

 New York, NY 10019 
 Dear Chris: 

 

	1.	 Haymaker Acquisition Corp. II (together with any present and future subsidiaries and/or affiliates of Haymaker
Acquisition Corp. II, the “Company”) hereby retains Stifel, Nicolaus & Company, Incorporated (“Stifel”) to provide non-exclusive capital markets advisory and related services in
connection with the Company’s initial public offering of units (“IPO”) and any potential business combination with a target company (the “Target”, or in the case of multiple potential targeted companies, the
“Targets”) as contemplated by the registration statement in connection with the IPO (“Engagement”). 

  

	2.	 In such capacity: 

  

	 	(a)	 The capital markets advisory and related services to be rendered by Stifel pursuant to the Engagement in
connection with the IPO shall include: (i) advising on timing, sizing and structuring considerations; (ii) assisting the Company in the review of presentations to be used in meetings with potential investors in connection with the IPO; and
(iii) providing such other capital markets advisory services as the Company and Stifel may agree upon. 

  

	 	(b)	 The capital markets advisory and related services to be rendered by Stifel pursuant to the Engagement in
connection with a potential business combination shall include: (i) advising on potential sources and Targets for a business combination; (ii) advising on transaction structuring considerations; (iii) assisting with benchmarking and
valuation analyses; (iv) advising on potential new shareholders in connection with a potential business combination; (v) arranging meetings with existing shareholders and potential new shareholders in connection with a potential business
combination; (vi) advising and assisting the Company on presentations to be used in roadshow and other meetings with existing and potential new shareholders and assisting the Company on shareholder positioning considerations; and
(vii) providing such other capital markets advisory and related services as the Company and Stifel may agree upon. 

  

	 	(c)	 For the avoidance of doubt, the services to be provided in connection with the IPO described in
Section 2(a) shall not include activities involving the solicitation or distribution of any offering of any securities, such as participation in the preparation of the offering or other documents, participation in the distribution of any
offering, or the furnishing of customer and/or broker lists for solicitation. Stifel shall not be deemed to be an underwriter for any securities of the Company, and Stifel shall have no liability for any disclosures or other information or
representations provided by the Company to investors or to any other person. 

  

	 	(d)	 The capital markets advisory and related services described in Section 2(b) are not intended to and shall
not include services customarily performed or provided pursuant to separate agreements for the provision of merger and acquisition advisory services (“M&A Advisory Services”). Any such M&A Advisory Services, as well as any
investment banking services related to the private placement of (i) equity, equity-linked or convertible PIPE, (ii) senior, subordinated or other debt, or (iii) any other securities of the Company, are collectively beyond the scope of
the Engagement and shall be subject to separate engagements and additional compensation as agreed by the parties hereto. 

  

	 	(e)	 The Company acknowledges and agrees that Stifel, if requested to provide services, will be entitled to provide
its services, in whole or in part, through any current or future affiliate and references to Stifel shall, where the context so requires, include reference to any such affiliate. 

 

	 	(f)	 Notwithstanding the foregoing, Stifel shall not be required to engage in any activities that could be deemed to
be proxy solicitation in connection with the business combination or that would require the listing of Stifel’s name as the Company’s or the Targets’ proxy solicitation agent in any proxy or information statement or other document
filed with the Securities and Exchange Commission. The Company agrees to provide, or cause to be provided, customary representations or warranties to Stifel if reasonably requested by Stifel in connection with any offering, placement or transfer of
securities of the Company. 

	3.	 Stifel is being retained to serve as financial advisor only to the Company, and it is agreed that the
engagement of Stifel is not, and shall not be deemed to be, on behalf of, and is not intended to confer rights or benefits upon, any shareholder or creditor of the Company or upon any other person or entity. No one other than the Company is
authorized to rely upon this engagement of Stifel or any statements, conduct or advice of Stifel, and no one other than the Company is intended to be a beneficiary of this engagement. All opinions, advice or other assistance (whether written or
oral) given by Stifel in connection with this engagement are intended solely for the benefit and use of the Company and will be treated by the Company as confidential, and no opinion, advice or other assistance of Stifel shall be used for any other
purpose or reproduced, disseminated, quoted or referred to at any time, in any manner or for any purpose, nor shall any public or other references to Stifel (or to such opinions, advice or other assistance) be made, without the express prior written
consent of Stifel. 

  

	4.	 The Company will furnish Stifel with all information and material concerning the Company, the IPO, the Targets
and any potential business combination which Stifel requests in connection with the performance of its obligations hereunder. The Company represents and warrants that all information regarding the Company, the IPO, the Targets and the business
combination made available to Stifel by the Company will, at all times during the period of the engagement of Stifel hereunder, be complete and correct in all material respects and will not contain any untrue statement of a material fact or omit to
state a material fact necessary in order to make the statements therein not misleading in light of the circumstances under which such statements are made. The Company further represents and warrants that any projections provided to Stifel will have
been prepared in good faith and will be based upon assumptions which, in light of the circumstances under which they are made, are reasonable. The Company acknowledges and agrees that in rendering its services hereunder Stifel will be using and
relying upon, without any independent investigation or verification thereof, all information that is or will be furnished to Stifel by or on behalf of the Company or the Targets and on publicly available information, and Stifel will not in any
respect be responsible for the accuracy or completeness of any of the foregoing kinds of information, and that Stifel will not undertake to make an independent appraisal of any of the assets or businesses of the Company or the Targets. The Company
understands that in rendering services hereunder Stifel does not provide accounting, legal or tax advice and will rely upon the advice of counsel to the Company and the Targets and other advisors to the Company and the Targets as to accounting,
legal, tax and other matters relating to any transaction or proposed transaction contemplated by this letter agreement (the “Agreement”). 

  

	5.	 (a) In addition to the obligation of the Company to pay certain expenses set forth in Section 6, if a
transaction is consummated with a Target in connection with a business combination, the Company will pay up to $50,000 of Stifel’s reasonable and documented
out-of-pocket expenses (including, without limitation, expenses relating to document and presentation materials, travel, external database and communications services,
courier and delivery services, and the fees and expenses of Stifel’s outside legal counsel), incurred by Stifel in connection with this engagement. Any expense in excess of $10,000 in the aggregate shall require the Company’s prior written
consent (which may be via email). Such out-of-pocket expenses shall be payable upon the receipt of an invoice from Stifel or upon closing of the business combination
with a Target. If any compensation or expenses payable to Stifel pursuant to this Agreement are not fully paid when due, the Company agrees to pay all costs of collection or other enforcement of Stifel’s rights hereunder, including but
not limited to reasonable attorneys’ fees and expenses, whether collected or enforced by suit or otherwise. 

 (b)
Promptly upon closing of the Company’s IPO (with the closing of such IPO during the term of this Agreement or at any time during a period of (12) months following the termination of Stifel’s engagement hereunder), the Company shall
cause the lead underwriter of the IPO to pay Stifel a cash fee for advisory services equal to $1.0 million on behalf of the Company. 

(c) In connection with the IPO and upon prior or simultaneous receipt of the fee in section 5(b), Stifel agrees that it will purchase in a
private placement (the “Private Placement”) warrants in an amount equal to $100,000 (whether or not the over-allotment option is exercised). The Private Placement is expected to close simultaneously with the completion of the IPO and any
other concurrent private placement, subject to customary terms and conditions to be mutually agreed upon by the parties. Stifel acknowledges that its warrants will be subject to pro rata cutback or other restructuring (including, but not limited to,
exchange, lock-up or other modifications) at the time of the business combination on the same terms as the sponsor warrants, in the Company’s sole and absolute discretion. 

(d) Upon the closing of a business combination with a Target (with the closing of such transaction during the term of this Agreement or at any
time during a period of thirty-six (36) months following the termination of Stifel’s engagement hereunder)C, then the Company shall pay or cause to be paid to Stifel (a) in the event the
underwriter exercises its overallotment option in full, a cash fee equal to $3,243,750; (b) in the event the underwriter does not exercise its overallotment option at all, a cash fee equal to $2,625,000; (c) in the event the underwriter partially
exercises its overallotment option, a cash fee equal to 25% of the sum of (i) 3.5% multiplied by $300 million and (ii) 5.5% multiplied by the overallotment exercise amount. 

	6.	 In connection with engagements of the nature covered by this Agreement, it is Stifel’s practice to provide
for indemnification, contribution, and limitation of liability. By signing this Agreement, the Company agrees to the provisions attached to this Agreement (Attachment A), which provisions are expressly incorporated by reference herein.

  

	7.	 The Company represents and warrants to Stifel that this Agreement has been duly authorized and represents the
legal, valid, binding and enforceable obligation of the Company and that this Agreement does not require the approval or consent of any governmental or regulatory agency or violate any law, regulation, contract or order binding on the Company. The
Customer Due Diligence Requirements for Financial Institutions Rule (the “CDD Rule”) promulgated by the Financial Crimes Enforcement Network (“FinCEN”) requires Stifel to identify and verify the identity of beneficial owners of
its legal entity clients. Unless an exemption to the CDD Rule applies, the Company agrees to cooperate with, and provide to, Stifel all information and documents required by FinCEN in order to comply with the CDD Rule. 

 

	8.	 The term of this engagement will continue until terminated by either party at any time by giving the other
party at least 30 days’ prior written notice. After any termination of this engagement by the Company, the Company acknowledges and agrees that Stifel shall be free to provide services to or represent the Targets in any capacity in connection
with any transaction contemplated by the Targets subsequent to termination of this engagement. The provisions of Sections 3, 4, 5, 6, 7, 9, 10, 11, 12 and 13, hereof shall survive any expiration or termination of this Agreement.

  

	9.	 The Company agrees that, following the closing or consummation of any transaction contemplated by this
Agreement, Stifel has the right to place an announcement on its website and/or advertisements in financial and other newspapers and journals at its own expense, describing its services to the Company and a general description of the transaction,
with the prior approval of the Company not to be unreasonably withheld. In addition, the Company agrees to include in any press release or public announcement announcing a transaction a reference to Stifel’s role as financial advisor to the
Company with respect to such transaction, provided that the Company will submit a copy of any such press release or public announcement to Stifel for its prior approval, which approval shall not be unreasonably withheld or delayed.

  

	10.	 The Company represents and warrants that there are no brokers, representatives or other persons which have an
interest in any compensation due to Stifel from any transaction contemplated herein. The Company acknowledges and agrees that Stifel is a full-service securities firm which may be engaged at various times, either directly or through its affiliates,
in various activities including, without limitation, securities trading, investment management, financing and brokerage activities and financial advisory services for companies, governments and individuals. In the ordinary course of these
activities, which may conflict with the interests of the Company, Stifel and its affiliates from time-to-time may: (i) effect transactions for its own account or
the accounts of its clients and hold long or short positions in debt or equity securities or other financial instruments (or related derivative instruments) of the Company, the Targets or other parties which may be the subject of this engagement or
any transaction contemplated hereby; (ii) have had confidential discussions with, and provided information to, clients, potential clients, financial investors or other parties in the Company’s or the Targets’ industry (including
competitors) regarding various market and strategic matters (including potential strategic alternatives or transactions that may involve the Company), provided, however, that this clause (ii) shall not limit any confidentiality obligations
Stifel may have at any time in favor of the Company; and/or (iii) have performed, or sought to perform, various investment banking, financial advisory or other services for clients who may have conflicting interests with respect to the Company
(including, without limitation, the Targets). 

  

	11.	 The terms and provisions of this Agreement are solely for the benefit of the Company and Stifel and the other
Indemnified Persons (as defined in Attachment A) and their respective successors, assigns, heirs and personal representatives, and no other person or entity shall acquire or have any right by virtue of this Agreement. The Company and Stifel
acknowledge and agree that Stifel is acting as an independent contractor, and is not a fiduciary of, nor will its engagement hereunder give rise to fiduciary duties to, the Company, the Targets or their respective shareholders. This Agreement
represents the entire understanding between the Company and Stifel with respect to Stifel’s engagement hereunder, and all prior discussions are merged herein. This Agreement may be executed in two or more counterparts (including fax or
electronic counterparts), all of which together will be considered a single instrument. THIS AGREEMENT SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW YORK WITHOUT REGARD TO SUCH STATE’S PRINCIPLES OF
CONFLICTS OF LAWS, AND MAY BE AMENDED, MODIFIED OR SUPPLEMENTED ONLY BY WRITTEN INSTRUMENT EXECUTED BY EACH OF THE PARTIES HERETO, WHICH IN THE CASE OF STIFEL MUST BE EXECUTED EITHER BY STIFEL’S HEAD OF INVESTMENT BANKING OR CHIEF OPERATING
OFFICER-INVESTMENT BANKING. 

	12.	 The parties hereby submit to the jurisdiction of and venue in the federal courts located in the New York, New
York in connection with any dispute related to this Agreement, any transaction contemplated hereby, or any other matter contemplated hereby. If for any reason jurisdiction and/or venue is unavailable in such federal courts, then the parties hereby
submit to the jurisdiction of and venue in the state courts located in such city in connection with any such dispute or matter. In addition, the parties hereby waive any right to a trial by jury with respect to any such dispute or matter.

  

	13.	 Trust Waiver. Stifel hereby acknowledges and agrees that neither it nor any Indemnified Person seeking
indemnity under this Agreement has any right of set-off or any right, title, interest or claim of any kind (“Trust Account Claim”) to, or to any monies or other assets in, the trust account holding
the net proceeds of the IPO and any private placement proceeds (the “Trust Account”), and hereby irrevocably waives any Trust Account Claim to, or to any monies or other assets in, the Trust Account (or distribution therefrom) that it or
any Indemnified Person may have now or in the future. In the event Stifel has any Trust Account Claim against the Company under this Agreement or otherwise, Stifel shall pursue such Trust Account Claim solely against the Company and its assets
outside the Trust Account and not against the Trust Account (or distribution therefrom) or any monies or other assets in the Trust Account. 

If the foregoing correctly sets forth the entire understanding and agreement between Stifel and the Company, please so indicate in the space provided for that
purpose below and return an executed copy to us, whereupon this Agreement shall constitute a binding agreement as of the date first above written. 
  

			
		 	Very truly yours,
		
	By:	 	STIFEL, NICOLAUS & COMPANY, INCORPORATED
		
		 	Investment Banking
		
	By:	 	/s/ Chris
Hagar                                        
        
	Name:	 	Chris Hagar
	Title:	 	Managing Director

 AGREED: 
 HAYMAKER
ACQUISITION CORP. II 
  

			
	By:	 	/s/ Chris Bradley
	Name:	 	Chris Bradley
	Title:	 	Chief Financial Officerex_145923.htm

Exhibit 10.1

 

Certain identified information has been excluded from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.

 

AMENDMENT TO EXHIBIT B OF MANUFACTURING AND SUPPLY AGREEMENT

 

IsoRay Medical, Inc., a Delaware corporation with offices at 350 Hills Street, Suite 106, Richland, WA 99352 (“IsoRay”), and GT Medical Technologies, Inc., a Delaware corporation having its principal place of business at 1809 S. Holbrook Lane, Suite 107, Tempe, AZ 85281 (“GT Med Tech”), previously entered into an Amended and Restated Manufacturing and Supply Agreement dated April 26, 2019 (the “Agreement”). The parties now desire to modify the pricing of Exhibit B of the Agreement as outlined on the attached page.

 

In witness whereof, the parties have caused their respective authorized representatives to execute this Amendment to Exhibit B of the Manufacturing and Supply Agreement as of May 28, 2019 (“the Effective Date”).

 

 

	GT Medical Technologies, Inc. 	 	IsoRay Medical, Inc.
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	By: /s/ Hernan Lopez	 	 	By: /s/ Jonathan Hunt	 
	 	 	 	 	 
	Name: Hernan Lopez 	 	 	Name: Jonathan Hunt	 
	 	 	 	 	 
	Title: Vice President of Operations 	 	Title: Chief Financial Officer

         

 

 

 

Exhibit B

Open-Book Pricing Formula & Pricing Schedule

 

Open-Book Pricing Formula for GammaTileTM 3-pack Product

	
			Description

				
			Price

			
	
			Materials (excluding Duragen)

				
			$110.37

			
	
			Labor

				
			[**]

			
	
			50% Profit Margin

				
			[**]

			
	
			Seeds (high activity 3.5U Cesium-131 source – assumes 4 seeds per GammaTileTM)

				
			[**]

			
	
			Overhead*

				
			[**]

			
	 	 
	
			Total price of each GammaTileTM 3-pack Product

				
			[**]

			

 

Open-Book Pricing Formula for GammaTileTM 6-pack Product

	
			Description

				
			Price

			
	
			Materials (excluding Duragen)

				
			$135.24

			
	
			Labor

				
			[**]

			
	
			50% Profit Margin

				
			[**]

			
	
			Seeds (high activity 3.5U Cesium-131 source – assumes 4 seeds per GammaTileTM)

				
			[**]

			
	
			Overhead*

				
			[**]

			
	 	 
	
			Total price of each GammaTileTM 6-pack Product

				
			[**]

			

 

Open-Book Pricing Formula for Duragen Validation

	
			Description

				
			Price

			
	
			Materials (excluding Duragen)

				
			$28.62

			
	
			Labor

				
			[**]

			
	
			50% Profit Margin

				
			[**]

			
	
			Simulation Seeds

				
			[**]

			
	
			Overhead

				
			[**]

			
	 	 
	
			Total price of each Duragen Validation

				
			[**]

			

 

 

Pass-Through Costs

	 	
			●

				
			Sterilization: Sterilization costs shall be billed either directly to GT Med Tech or invoiced as a separate line item as a pass-through cost by IsoRay. No mark-up to sterilization or other pass-through costs for the Product will be assessed by IsoRay.

			

	 	
			●

				
			Bacterial Endotoxin Testing: Bacterial Endotoxin Testing (“BET”) costs shall be billed either directly to GT Med Tech or invoiced as a separate line item as a pass-through cost by IsoRay. No mark-up to BET or other pass-through costs for the Product will be assessed by IsoRay.

			

 

*The Overhead charge is to compensate Isoray for assistance with facility radioactive materials licenses, customer support activities, quality assurance and regulatory assurance including upkeep of supplier qualifications (not including site visits or audits), risk assessments, and compliance maintenance, and general administration associated with the pass-through costs.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00296-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00296-of-00352.parquet"}]]